Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication.

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Abstract Text:

Sho-ichi Yamagishi,Kazuo Nakamura,Takanori Matsui,Yoshihiro Noda,Tsutomu Imaizumi,Sho-Ichi Yamagishi,Kazuo Nakamura,Takanori Matsui,Yoshihiro Noda,Tsutomu Imaizumi,

Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Although several hyperglycemia-elicited metabolic and hemodynamic derangements have been implicated in the pathogenesis of diabetic vascular complication, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the theory 'hyperglycemic memory'. Further, there is a growing body of evidence that AGEs and their receptor (RAGE) axis is involved in the pathogenesis of diabetic vascular complication. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells, thus playing an important role in the development and progression of diabetic micro- and macroangiopathy. These observations suggest that down-regulation of RAGE expression or blockade of the RAGE downstream signaling may be a promising target for therapeutic intervention in diabetic vascular complication. In this review, we discuss several types of agents that could potentially inhibit RAGE expression or its downstream pathways and their therapeutic implications in diabetic vascular complication.

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Publishing Authors By Initials

S Yamagishi,K Nakamura,T Matsui,Y Noda,T Imaizumi,S Yamagishi,K Nakamura,T Matsui,Y Noda,T Imaizumi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current pharmaceutical design

VOLUME: 14

Page Numbers: 487-95

Journal Abbreviation: Curr. Pharm. Des.

ISSN: 1873-4286

DAY: 21

MONTH: 02

YEAR: 2008

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9602487

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication.

AFFILIATION: Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Pharm Des

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Receptor for Advanced Glycation End Products RAGE: A Novel Therapeutic Target for Diabetic Vascular Complication Related Publications

• A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes.
• Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
• Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications.
• Antiatherogenic effect of isoflavones in ovariectomized apolipoprotein e-deficient mice.
• Bilateral pseudocysts of the auricles.
• CORRELATION BETWEEN BRAIN CATECHOLAMINE AND SEDATIVE ACTION OF RESERPINE.
• Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment.
• Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
• Colorectal polypectomy and risk of colorectal cancer by subsite: the Fukuoka Colorectal Cancer study.
• Detection of coronary artery stenosis after successful percutaneous coronary intervention by dipyridamole stress portable type signal-averaged electrocardiography: a prospective study.
• Effects of milk fermented byLactobacillus gasseri SBT2055 on adipocyte size in rats.
• FKF1 and GIGANTEA complex formation is required for day-length measurement in Arabidopsis.
• Inhibitors of Advanced Glycation End Products (AGEs): Potential Utility for the Treatment of Cardiovascular Disease.
• LXR Agonist Increases the Lymph HDL Transport in Rats by Promoting Reciprocally Intestinal ABCA1 and apo A-I mRNA Levels.
• Lumbosacral subdural hematoma following a ruptured aneurysmal subarachnoid hemorrhage.
• Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
• Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
• Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
• Oxidative stress is related to exercise intolerance in patients with heart failure.
• PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.
• Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.
• Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication.
• Reply to Letter Regarding Article, "Effect of Autologous Bone-marrow Cell Transplantation on Ischemic Ulcer in Patients With Buerger's Disease".
• Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population.
• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects.
• The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography.
• The properties of ATPase of synaptic vesicle fraction.
• Vitamin C reversed malfunction of peripheral blood-derived mononuclear cells in smokers through antioxidant properties.
• [Internal secretion and hypertension. Catecholamine metabolism and changes in it.]
• [Prognosis and molecular pathogenesis of adult T-cell leukemia/lymphoma]